Abtis
AbTis, founded in 2016 and acquired by Dong-A ST in 2023, is a South Korean biotechnology company specializing in site-selective antibody conjugation. Its ADC linker technology, AbClick®, allows for cost-effective ADC production with ‘off-the-shelf’ antibodies without altering their characteristics. Focusing on solid tumors, AbTis develops its own ADC pipelines using AbClick® and collaborates with global partners. AbTis aims to improve patient outcomes through innovative research, positioning itself as a leader in the biopharmaceutical industry.
